HIT — Health In Tech Income Statement
0.000.00%
- $36.31m
- $28.73m
- $19.49m
Annual income statement for Health In Tech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 5.77 | 19.2 | 19.5 |
Cost of Revenue | |||
Gross Profit | 5.44 | 16.8 | 15.4 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Total Operating Expenses | 5.56 | 15.8 | 18.5 |
Operating Profit | 0.206 | 3.38 | 0.99 |
Total Net Non Operating Interest Income / Expense | |||
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | 0.201 | 3.42 | 0.889 |
Provision for Income Taxes | |||
Net Income After Taxes | 0.08 | 2.48 | 0.67 |
Minority Interest | |||
Net Income Before Extraordinary Items | |||
Extraordinary Items | |||
Net Income | 0.08 | 2.48 | 0.67 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 0.08 | 2.48 | 0.67 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 0.007 | 0.018 | 0.012 |